We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer (LDE225)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02111187
Recruitment Status : Completed
First Posted : April 11, 2014
Results First Posted : March 7, 2019
Last Update Posted : March 7, 2019
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Brief Summary:

This trial is designed as a randomized two-arm (LDE225 vs. observation groups) open-label prospective clinical trial in men with localized high-risk prostate cancer undergoing radical prostatectomy.

The investigators propose to determine the effects of LDE225 on neoplastic prostate tissue from men at high risk of systemic disease progression, by comparing pre-surgical core-biopsy specimens to tumor tissue harvested at the time of prostatectomy.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: LDE225 Phase 1

Detailed Description:
High-risk patients will be identified based on their core-needle biopsy features, PSA levels, and clinical stage. After obtaining baseline laboratory and clinical values (including an ECG, PSA, hematologic, and renal and hepatic panels), men will receive oral LDE225 800 mg/day or observation daily for 4 weeks (±3 days) prior to prostatectomy. Patients will have a clinical visit and an ECG and laboratory testing will be performed at 2 weeks and then again at 4 weeks, including a 4-week pre-prostatectomy measurement of PSA and a blood sample to determine plasma LDE225 levels. Men will undergo radical prostatectomy (with bilateral pelvic lymphadenectomy as appropriate), at which point two 250-mg biopsies of prostate tissue will be obtained, frozen and stored for analysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.
Actual Study Start Date : April 2014
Actual Primary Completion Date : January 18, 2017
Actual Study Completion Date : January 18, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Sonidegib

Arm Intervention/treatment
Active Comparator: LDE225 (Arm1)
Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
Drug: LDE225
Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
Other Name: Sonidegib

No Intervention: Observation Arm (Arm2)
Observation Arm (Arm2) will receive no treatment prior to prostatectomy.

Primary Outcome Measures :
  1. Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation) [ Time Frame: Up to 3 Years ]
    This was defined as the number of patients who achieved at least a two-fold reduction in GLI1 expression in post-treatment vs. pre-treatment tumor tissues.

Secondary Outcome Measures :
  1. Percentage of Participants With a Pathological Effect of Presurgical Treatment With LDE225 [ Time Frame: Up to 3 years ]
    To determine whether presurgical treatment with LDE225 can exert a pathological effect on high-risk tumors (i.e. increase apoptosis, decrease proliferation).

  2. Effect of LDE225 on PSA Recurrence Following Prostatectomy [ Time Frame: Up to 3 years ]
    To evaluate whether presurgical treatment with LDE225 diminishes the risk of PSA recurrence following prostatectomy.

  3. Number of Participants With Adverse Events in Each Group (LDE225 and Observation) [ Time Frame: Up to 3 years ]
    Safety and tolerability, including any drug-related toxicities of Sonidegib, were reported via CTCAE version 4.0.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide written informed consent prior to any screening procedures.
  2. Age 18 years or older.
  3. Histologically-documented prostatic adenocarcinoma in ≥2 cores
  4. ECOG performance status ≤2
  5. Localized prostate cancer with at least one of the following NCCN high-risk features:

    • Gleason sum ≥8
    • PSA >20 ng/mL
    • Clinical stage ≥T3
  6. Must be a candidate for radical prostatectomy
  7. No evidence of known metastatic disease (M0 or Mx allowed)
  8. Adequate bone marrow, liver and renal function as specified below:

    • Absolute neutrophil count (ANC) ≥ 1500/µL
    • Hemoglobin (Hgb) ≥ 9.0 g/dL
    • Platelets ≥100,000/µL
    • Serum total bilirubin ≤ 1.5 x ULN (upper limit of normal)
    • AST and ALT ≤ 2.5 x ULN
    • Plasma creatine phosphokinase (CK) < 1.5 x ULN, if known
    • Serum creatinine ≤ 1.5 x ULN [or 24-hour creatinine clearance ≥ 50ml/min]
  9. Patient is able to swallow and retain oral medications

Exclusion Criteria:

  1. Patients who have had major surgery within 4 weeks of enrollment.
  2. Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study.
  3. Patients unable to take oral drugs (e.g. lack of physical integrity of the upper GI tract or known malabsorption syndromes).
  4. Patients who have previously been treated with LDE225 or other Hh pathway inhibitors
  5. Patients who have neuromuscular or muscular disorders (e.g. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are known to cause rhabdomyolysis (such as statins and fibrates), and that cannot be discontinued at least 2 weeks prior to starting LDE225. If it is essential that the patient stays on a statin for hyperlipidemia, only pravastatin may be used with extra caution. Patients should not plan to embark on a new strenuous exercise regimen after initiation of study treatment. (NB: Muscular activities, such as strenuous exercise, that can result in significant increases in plasma CK levels should be avoided whilst on LDE225 treatment).
  6. Patients who have taken part in an experimental drug study within 4 weeks or 5 half-lives (whichever is longer) of initiating treatment with LDE225.
  7. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting LDE225.
  8. Patients taking moderate/strong inhibitors or inducers of CYP3A4/5 or drugs metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be discontinued before starting treatment with LDE225. Medications that are strong CYP3A4/5 inhibitors should be discontinued for at least 7 days and strong CYP3A/5 inducers for at least 2 weeks prior to starting treatment with LDE225.
  9. No concurrent use of statins (except for pravastatin, if absolutely necessary)
  10. No concurrent warfarin or Coumadin-derivatives
  11. Impaired cardiac function or significant heart disease, including any one of the following:

    • Angina pectoris within 3 months
    • Acute myocardial infarction within 3 months
    • QTc >450 msec on the screening ECG
    • A past medical history of clinically significant ECG abnormalities or a family history of prolonged QT-interval syndrome
    • Other clinically significant heart disease (e.g. heart failure, uncontrolled/labile hypertension, or history of poor compliance with an antihypertensive regimen)
  12. Patients who are not willing to apply highly effective contraception during the study and through the duration of LDE225 treatment.

    • Male patients must use highly effective (double barrier) methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the study, and continuing using contraception and refrain from fathering a child for 6 months following the last dose of the study drug. A condom is also required to be used by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the study treatment via seminal fluid. Sexually active males must be willing to use a condom during intercourse while taking the study drug and for 6 months after stopping investigational medications and agree not to father a child during this period.
  13. Patients unwilling or unable to comply with the research protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02111187

Layout table for location information
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Layout table for investigator information
Principal Investigator: Emmanuel Antonarakis, M.D. Johns Hopkins University
  Study Documents (Full-Text)

Documents provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
Layout table for additonal information
Responsible Party: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ClinicalTrials.gov Identifier: NCT02111187    
Other Study ID Numbers: J1402
NA_00091602 ( Other Identifier: JHMIRB )
First Posted: April 11, 2014    Key Record Dates
Results First Posted: March 7, 2019
Last Update Posted: March 7, 2019
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins:
High risk localized prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases